2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Chau Dang, MD, medical oncologist, chief, West Harrison Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the potential of neratinib as a combination treatment for patients with HER2-positive breast cancer.
Chau Dang, MD, medical oncologist, chief, West Harrison Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the potential of neratinib as part of a combination treatment for patients with HER2-positive breast cancer.
Currently, neratinib is being explored in combination with capecitabine versus lapatinib plus capecitabine in the phase III NALA study for HER2-positive patients who have received more than 2 treatments. This trial will allow researchers to determine whether this combination can be another treatment option for patients.
Dang explains that the incidence of grade 3 diarrhea associated with neratinib is an ongoing and significant issue; however, this toxicity can be managed through anti-diarrheal agents. Other small molecules are being developed in order to target these patients who also have brain metastases.
Related Content: